middle.news
Imagion Biosystems Clears FDA to Start Phase 1b/2 Breast Cancer Trial
9:05am on Tuesday 2nd of June, 2026 AEST
•
Healthcare
Read Story
Imagion Biosystems Clears FDA to Start Phase 1b/2 Breast Cancer Trial
9:05am on Tuesday 2nd of June, 2026 AEST
Key Points
FDA clears IND for MagSense® HER2 Imaging Agent
Phase 1b/2 trial recruitment to begin Q3 2026
Trial designed to optimize dosing and diagnostic performance
MagSense® offers radiation-free molecular MRI cancer detection
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE